RT杂志文章SR电子T1 Tezepelumab降低哮喘患者的基质重塑和炎症通路JF欧洲呼吸杂志JO Eur Respir J FD欧洲呼吸学会SP RCT3785 DO 10.1183/13993003.大会-2019。188bet官网地址RCT3785 VO 54 IS supl 63 A1 Sridhar, Sriram A1 Zhao, Wei A1 Pham, Tuyet-Hang A1 Kearley, Jennifer A1 White, Wendy I. A1 Wu, Yuling A1 Parnes, Jane R. A1 Roskos, Lorin K. A1 Griffiths, Janet M. YR 2019 UL //www.qdcxjkg.com/content/54/suppl_63/RCT3785.abstract AB背景:Tezepelumab是一种人单克隆抗体，可选择性阻断胸腺基质淋巴生成素与其受体相互作用(TSLP)，与安慰剂相比，改善了严重、不受控制的哮喘患者的临床结果(2b期通路研究[NCT02054130])。进行蛋白质组学分析，以进一步阐明tezepelumab在哮喘患者中的活性机制。目的:确定替泽单抗改变了哪些血清蛋白。方法:患者随机分为tezepelumab治疗组和安慰剂组(Corren et al.;NEJM 2017; 377:936-46)。使用基于医学的无数规则(RBM)和SomaLogic平台(分别为122和1305个分析物)在基线和治疗后的多个时间点评估血清蛋白水平，直到第52周。在每个时间点通过方差分析和t检验确定显著变化，并评估与基线相比的变化百分比。我们还探讨了RBM蛋白基线水平与临床生物标志物之间的关系。结果:基质重塑(MMP-10，骨膜蛋白)、嗜酸性粒细胞相关(IL5RA, PAPP - A)、IgE和TARC蛋白水平在治疗后显著降低(第52周tezepelumab组与安慰剂组> %变化，p<0.05)。 At baseline, MMP-10 and periostin correlated significantly (p<0.01) with blood eosinophils (bEOS) and FENO levels.Conclusions: Tezepelumab led to a decrease in biomarkers of inflammation and matrix remodelling, which were correlated with bEOS and FENO levels at baseline. Modulation of matrix remodelling proteins may reflect a novel mechanism of action for tezepelumab in addition to the inhibition of airway inflammation.Co-sponsored by MedImmune, a member of the AstraZeneca Group, and Amgen Inc.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, RCT3785.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).